Climb Global Solutions enters its Q2 print on July 30 with the same central tension that defined yesterday's preview — a 31.7% short float and a stock that has refused to cooperate with bears — now sharpened by the fact that the report lands today.
The short positioning remains at extremes. Short interest has climbed a further 7% over the past week to 1.44 million shares, keeping nearly a third of the free float sold short. The ORTEX short score edged to 62.4 on July 28, its highest reading of the past two weeks, as the bearish structural case has grown heavier even as the stock added another 0.8% on Tuesday to close at $28.41. That 27% one-month gain means anyone who built a short position when the CEO and CFO were selling in the $80–$89 range back in March is nursing deep losses at current prices. Days to cover sits at 8.4 — meaning it would take more than eight average trading sessions for shorts to fully unwind — which compounds the squeeze risk going into any upside surprise.
The lending market gives bears no particular relief here, but it also contains the squeeze risk. Availability runs near 395% — roughly four shares remain available for every one currently borrowed — and borrowing costs are modest at 0.54%. That loose borrow environment means new short supply can still enter the market easily, which is why the elevated short interest has not already triggered a more violent covering rally. The divergence between a structurally crowded short book and a well-supplied lending pool is the key puzzle: bears are numerous, but they are not yet cornered.
The bull and bear cases reflect a company at a genuine inflection point. Bulls point to the Interworks acquisition, emerging-tech software distribution momentum, and expectations for adjusted EBITDA and EPS growth in 2026 and 2027. The EV/EBITDA multiple of roughly 9x and a PE near 17x remain modest for a distributor posting strong billings growth. Bears counter that adjusted EBITDA margins have been compressing and client concentration is rising — a combination that makes the growth story fragile if any single large relationship deteriorates. The sole covering analyst, Barrington Research, maintained its Outperform rating in May but with a $30 target that is already below the current price of $28.41, offering limited upside validation. Analyst data here is over 80 days old, so the Street's current view is largely unrefreshed heading into the print.
The Q2 report will test whether the revenue and billings trajectory can sustain the valuation re-rating the stock has already priced in — and whether margin trends show any sign of stabilising, the one variable that would most directly challenge the bear thesis.
See the live data behind this article on ORTEX.
Open CLMB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
